Peginesatide as a new approach for treating anemia of CKD patient: Is it like a falling star?

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 10, 2013, Pages 1277-1280

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Chronic kidney disease; Peginesatide; Safety

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE;

ANEMIA; CHRONIC KIDNEY DISEASE; CHRONIC PATIENT; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGENICITY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANEMIA; ANIMALS; DRUG HYPERSENSITIVITY; HEMATINICS; HUMANS; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84878879825     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.799139     Document Type: Review

References (15)

1. Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Exp Opin Pharmacother 2013;14:937-48
2. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11
3. Macdougall IC, Provenzano R, Sharma A, et al. PEARL Study Groups. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013;368:320-32
4. Fishbane S, Schiller B, Locatelli F, et al. EMERALD Study Groups. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19
5. Available from: http://omontys.com/[Last viewed on 26 February 2013]
6. Available from: http://medicalxpress.com/news/2013-02-fda-omontys.html [Viewed on 26 February 2013]
7. Fineberg SE, Galloway JA, Fineberg NS, et al. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983;25:465-9
8. Matsuda F, Torii Y, Enomoto H, et al. Anti-interferon-a neutralizing antibody is associated with nonresponse to pegylated interferon-a plus ribavirin in chronic hepatitis C. J Viral Hepat 2012;19:694-703
9. Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18:1775-81
10. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006;34:1303-11
11. Woodburn KW, Schatz PJ, Fong KL, Beaumier P. Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys. Int J Immunopathol Pharmacol 2010;23(1):121-9
12. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361:1848-55
13. Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures-2012. Am J Health Syst Pharm 2012;69:405-21
14. Woodburn KW, Wilson SD, Fong KL, et al. Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica 2008;93:1376-9
15. Siscovick DS, Sotoodehnia N, Rea TD, et al. Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the community. Rev Endocr Metab Disord 2010;11:53-9